Chou et al., 2007 - Google Patents
Transforming growth factor‐β1 suppresses hepatitis B virus replication primarily through transcriptional inhibition of pregenomic RNAChou et al., 2007
View PDF- Document ID
- 3281255882247700038
- Author
- Chou Y
- Chen M
- Hu C
- Chen Y
- Chong C
- Tsai Y
- Liu T
- Jeng K
- Chang C
- Publication year
- Publication venue
- Hepatology
External Links
Snippet
Transforming growth factor–beta1 (TGF‐β1) is a pleiotropic cytokine with pivotal roles in the regulation of cellular functions and immune responses. In this study, we found that TGF‐β1 was able to effectively suppress hepatitis B virus (HBV) replication. In the presence of TGF …
- 102100014320 TGFB1 0 title abstract description 184
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse Transcribing DNA Viruses
- C12N2730/00011—Reverse Transcribing DNA Viruses
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chou et al. | Transforming growth factor‐β1 suppresses hepatitis B virus replication primarily through transcriptional inhibition of pregenomic RNA | |
| Kuo et al. | HBV replication is significantly reduced by IL-6 | |
| Rehermann | Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells | |
| Pollicino et al. | Hepatitis B virus (HBV) induces the expression of interleukin-8 that in turn reduces HBV sensitivity to interferon-alpha | |
| Wu et al. | Immunopathogenesis of HBV infection | |
| Yang et al. | Enhanced expression of vascular endothelial growth factor‐A in ground glass hepatocytes and its implication in hepatitis B virus hepatocarcinogenesis | |
| Zhao et al. | Innate and adaptive immune escape mechanisms of hepatitis B virus | |
| Wang et al. | Hepatitis B e antigen inhibits NF-κB activity by interrupting K63-linked ubiquitination of NEMO | |
| Puro et al. | Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA | |
| Guy et al. | Intrahepatic expression of genes affiliated with innate and adaptive immune responses immediately after invasion and during acute infection with woodchuck hepadnavirus | |
| Kim et al. | The level of hepatitis B virus replication is not affected by protein ISG15 modification but is reduced by inhibition of UBP43 (USP18) expression | |
| Luo et al. | Autologus dendritic cell vaccine for chronic hepatitis B carriers: a pilot, open label, clinical trial in human volunteers | |
| Chen et al. | STING and liver disease | |
| Visvanathan et al. | Immunopathogenesis: role of innate and adaptive immune responses | |
| Liu et al. | PD-L1 upregulation by IFN-α/γ-mediated Stat1 suppresses anti-HBV T cell response | |
| Suresh et al. | Innate and adaptive immunity associated with resolution of acute woodchuck hepatitis virus infection in adult woodchucks | |
| Usai et al. | TNF-alpha inhibition ameliorates HDV-induced liver damage in a mouse model of acute severe infection | |
| Xiong et al. | Interferon-inducible MyD88 protein inhibits hepatitis B virus replication | |
| Torii et al. | Effectiveness and long-term outcome of lamivudine therapy for acute hepatitis B | |
| Real et al. | Hepatitis B virus genome replication triggers toll-like receptor 3-dependent interferon responses in the absence of hepatitis B surface antigen | |
| Xu et al. | Alpha‐kinase 1 (ALPK1) agonist DF‐006 demonstrates potent efficacy in mouse and primary human hepatocyte (PHH) models of hepatitis B | |
| Lee et al. | Oncogenesis and transforming viruses: the hepatitis B virus and hepatocellularcarcinoma–the etiopathogenic link | |
| JP2023089268A (en) | Therapeutic composition of hepatitis b, and evaluation method of replication activity of hepatitis b virus | |
| Durantel et al. | Innate response to hepatitis B virus infection: observations challenging the concept of a stealth virus | |
| Sun et al. | Review of cytokine profiles in patients with hepatitis |